Skip to main content

Advertisement

SpringerLink
Log in

SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Aims

Four single nucleotide polymorphisms (SNPs) exist in the promoter region of the osteopontin (OPN) gene, namely, the SNPs at nucleotide (nt) -155, -616, and -1748 showing linkage disequilibrium to each other, and an independent SNP at nt -443. The significance of these SNPs in the risk of hepatocellular carcinoma (HCC) development was examined in patients with hepatitis C virus (HCV).

Methods

The SNPs at nt -155 and nt -443 were analyzed in 120 patients with HCC. The promoter activity was measured in HepG2 cells by the dual-luciferase reporter assay. The electrophoretic mobility shift assay was performed using nuclear extracts from the cells.

Results

Peripheral platelet counts at the time of HCC detection were greater in women with homozygous deletion at nt -155 and C/C or C/T at nt -443 than in those showing other allelic combinations, while no such difference was observed in men. The promoter activity was greater in oligonucleotides with deletions at nt -155 and C at nt -443 than in those with other haplotypes. The mobility shift assay showed double and single complexes with oligonucleotides around nt -155 and nt -443, respectively. Binding activities were greater in deletion than in G in the case of the retarded complex in the former assay and in T than in C in the latter assay. The other complex in the former assay included SRY, showing an equivalent binding activity to oligonucleotides with both alleles.

Conclusion

OPN promoter SNPs may play a role in the sexual difference in the risk of HCC development through the regulation of OPN expression in patients with HCV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860–864

    Article  CAS  Google Scholar 

  2. Kawashima R, Mochida S, Matsui A, et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999;256:527–531

    Article  CAS  Google Scholar 

  3. Wang Y, Mochida S, Kawashima R, et al. Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver. J Gastroenterol 2000;35:696–701

    Article  CAS  Google Scholar 

  4. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998;29:1250–1254

    Article  CAS  Google Scholar 

  5. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Canc Res 1999;5:2271–2277

    CAS  Google Scholar 

  6. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Canc Epidemiol Biomarkers Prev 2004;13:487–491

    CAS  Google Scholar 

  7. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127–132

    Article  CAS  Google Scholar 

  8. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21: 515–523

    Article  CAS  Google Scholar 

  9. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416–423

    Article  CAS  Google Scholar 

  10. Pan HW, Ou YH, Peng SY. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003;98:119–127

    Article  CAS  Google Scholar 

  11. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19–24

    Article  CAS  Google Scholar 

  12. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Canc Metastasis Rev 2008;27:103–118

    Article  CAS  Google Scholar 

  13. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463–474

    Article  CAS  Google Scholar 

  14. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834–1842

    Article  CAS  Google Scholar 

  15. Zhao J, Dong L, Lu B, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008;135:956–968

    Article  CAS  Google Scholar 

  16. Mochida S, Hashimoto M, Matsui A, et al. Genetic polymorphysms in promoter region of osteopontin gene as a marker for predicting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004;313:1079–1085

    Article  CAS  Google Scholar 

  17. Chiu YW, Tu HF, Wang IK, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 2010;46:302–306

    Article  CAS  Google Scholar 

  18. D’Alfonso S, Barizzone N, Giordano M, et al. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2005;52:539–547

    Article  Google Scholar 

  19. Hendig D, Arndt M, Szliska C, Kleesiek K, Götting C. SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem 2007;53:829–836

    Article  CAS  Google Scholar 

  20. Chen J, Wu Q, Lu Y, et al. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 2010;55:456–461

    Article  CAS  Google Scholar 

  21. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 2006;43:980–986

    Article  CAS  Google Scholar 

  22. Giacopelli F, Marciano R, Pistorio A, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genom 2004;20:87–96

    Article  CAS  Google Scholar 

  23. Schultz J, Lorenz P, Ibrahim SM, et al. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009;48:14–23

    Article  CAS  Google Scholar 

  24. Nagoshi S. Sex- or gender-specific medicine in Hepatology. Hepatol Res 2008;38:219–224

    Article  Google Scholar 

  25. Rodriguez-Torres M, Rios-Bedoya CF, Rodriguez-Orengo J, et al. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol 2006;40:358–366

    Article  Google Scholar 

  26. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574–679

    Article  CAS  Google Scholar 

  27. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257–265

    Article  CAS  Google Scholar 

  28. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–739

    Article  CAS  Google Scholar 

  29. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:267–272

    Article  Google Scholar 

  30. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35(5 Suppl 2):S72–S78

    Article  Google Scholar 

  31. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0. Lyon: IARC Press; 2004

    Google Scholar 

  32. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552–558

    Article  CAS  Google Scholar 

  33. Ng IO, Ng MM, Lai EC, Fan ST. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer 1995;75:18–22

    CAS  PubMed  Google Scholar 

  34. Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 1997;92:1355–1358

    CAS  PubMed  Google Scholar 

  35. Fukuda S, Itamoto T, Amano H, et al. Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg 2007;31:345–352

    Article  Google Scholar 

  36. Sinclair A, Berta P, Palmer M, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240–244

    Article  CAS  Google Scholar 

  37. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005;40:381–388

    Article  CAS  Google Scholar 

  38. Ono E, Shiratori Y, Okudaira T, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999;15:192–200

    Article  Google Scholar 

  39. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650–655

    Article  CAS  Google Scholar 

  40. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006;101:2051–2059

    Article  CAS  Google Scholar 

  41. Diaz-Hernandez V, Leon del Rio A, Zamora M, Merchant-Larios H. Expression profiles of SRY and SOX9 in rabbit gonads: the classical model of mammalian sex differentiation. Sex Dev 2008;2:152–166

    Article  CAS  Google Scholar 

  42. Salas-Cortés L, Jaubert F, Bono M, Fellous M, Rosemblatt M. Expression of the human SRY protein during development in normal male gonadal and sex-reversed tissues. J Exp Zool 2001;290:607–615

    Article  Google Scholar 

  43. Montazer-Torbati F, Kocer A, Auquste A, et al. A study of goat SRY protein expression suggests putative new roles for this gene in the developing testis of a species with long-lasting SRY expression. Dev Dynam 2010;239:3324–3335

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research by the Japan Society for the Promotion of Science (JSPS; scientific research (C): 19590788).

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan

    Kazuhiro Hamaoka, Sumiko Nagoshi, Kayoko Sugawara, Kayoko Naiki, Yoshihito Uchida, Mie Inao, Nobuaki Nakayama, Kenji Fujiwara & Satoshi Mochida

  2. Yokohama Rosai Hospital, Labor Health and Welfare Organization, Yokohama, Japan

    Kazuhiro Hamaoka, Sumiko Nagoshi, Kayoko Sugawara, Kayoko Naiki, Yoshihito Uchida, Mie Inao, Nobuaki Nakayama, Kenji Fujiwara & Satoshi Mochida

Authors
  1. Kazuhiro Hamaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumiko Nagoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kayoko Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kayoko Naiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihito Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mie Inao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuaki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenji Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoshi Mochida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Mochida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamaoka, K., Nagoshi, S., Sugawara, K. et al. SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV. Hepatol Int 7, 683–692 (2013). https://doi.org/10.1007/s12072-012-9404-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9404-1

Keywords

Search

Navigation